000			03248nam a22006137a 4500
008			131223s20132013 xxu||||| |||| 00| 0 eng d
022			_a0735-1631
040			_aOvid MEDLINE(R)
099			_a22875663
245			_aNifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic.
251			_aAmerican Journal of Perinatology. 30(4):275-81, 2013 Apr.
252			_aAm J Perinatol. 30(4):275-81, 2013 Apr.
253			_aAmerican journal of perinatology
260			_c2013
260			_fFY2013
266			_d2013-12-24
520			_aCONCLUSION: CYP3A5 genotype influences the oral clearance of nifedipine in pregnant women. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
520			_aOBJECTIVE: To characterize the pharmacokinetics and pharmacogenetics of nifedipine in pregnancy.
520			_aRESULTS: Fourteen women had complete data to analyze. Four women (29%) expressed variant CYP3A5; three of these women were also CYP3A4*1B allele carriers. The mean half-life of nifedipine was 1.68 +/- 1.56 hours. The area under the curve from 0 to 6 hours for the women receiving nifedipine every 6 hours was 207 +/- 138 g.h /L. Oral clearance was different between high expressers and low expressers (232.0 +/- 37.8 g/mL versus 85.6 +/- 45.0 g/mL, respectively; p = 0.007).
520			_aSTUDY DESIGN: Pregnant women receiving oral nifedipine underwent steady-state pharmacokinetic testing over one dosing interval. DNA was obtained and genotyped for cytochrome P450 (CYP) 3A5 and CYP3A4*1B. Nifedipine and oxidized nifedipine concentrations were measured in plasma, and pharmacokinetic parameters were compared between those women who expressed a CYP3A5*1 allele and those who expressed only variant CYP3A5 alleles (*3,*6, or *7).
546			_aEnglish
650			_a*Cytochrome P-450 CYP3A/ge [Genetics]
650			_a*Nifedipine/pk [Pharmacokinetics]
650			_a*Obstetric Labor, Premature/pc [Prevention & Control]
650			_a*Polymorphism, Genetic
650			_a*Tocolytic Agents/pk [Pharmacokinetics]
650			_aAdolescent
650			_aAdult
650			_aAlleles
650			_aCohort Studies
650			_aDose-Response Relationship, Drug
650			_aFemale
650			_aGene Expression Regulation
650			_aGenotype
650			_aHumans
650			_aInfant, Newborn
650			_aNifedipine/ad [Administration & Dosage]
650			_aObstetric Labor, Premature/ge [Genetics]
650			_aPharmacogenetics
650			_aPregnancy
650			_aPregnancy Outcome
650			_aProspective Studies
650			_aStatistics, Nonparametric
650			_aTocolytic Agents/ad [Administration & Dosage]
650			_aYoung Adult
651			_aMedStar Health Research Institute
657			_aComparative Study
657			_aJournal Article
657			_aResearch Support, N.I.H., Extramural
700			_aUmans, Jason G
790			_aCaritis SN, Clark S, Clay JM, Haas DM, Hebert MF, Obstetric-Fetal Pharmacology Research Units Network, Quinney SK, Renbarger JL, Umans JG
856			_uhttp://dx.doi.org/10.1055/s-0032-1323590 _zhttp://dx.doi.org/10.1055/s-0032-1323590
942			_cART _dArticle
999			_c1427 _d1427